The role of non-invasive brain stimulation (NIBS) in post-stroke motor recovery: synergies with antihypertensive therapy

El papel de la estimulación cerebral no invasiva (NIBS) en la recuperación motora tras un accidente cerebrovascular: sinergias con la terapia antihipertensiva

Isomadinova Lola - assistant of the department of clinical laboratory diagnostics with the course of Clinical laboratory diagnostics of the faculty of postgraduate education. email: lolaisomadinova@gmail.com; https://orcid.org/0009-0006-2250-0833
Tairova Sakina - Doctor of Philosophy in Medical Sciences (PhD), Assistant Professor, Department of Pathological Physiology, Samarkand State Medical University, Uzbekistan; E-mail: oniks126@yandex.ru; https://orcid.org/0000-0002-8639-2468
Mirrakhimova Maktuba - DSc, associate professor of the department of Children Diseases, Pediatrics. Tashkent Medical Academy, https://orcid.org/0000-0003-2802-4357, e-mail: mmh.20@mail.ru
Davlatov Salim – DSc, associate professor of the Department of Faculty and Hospital Surgery. Bukhara State Medical Institute named after Abu Ali ibn Sino. Bukhara, Uzbekistan. https://orcid.org/0000-0002-3268-7156. e-mail: pro.ilmiy@bsmi.uz
Kadirov Bekhruzbek - assistance of the Department of Faculty and Hospital Therapy of the Bukhara State Medical Institute named after Abu Ali ibn Sino. Bukhara, Uzbekistan, https://orcid.org/0009-0009-1552-6367; e-mail: kadirov.bexruzbek@bsmi.uz
Yadgarova Shaxodat - PhD, Senior teacher of the Department of Hygiene No.2 of the Bukhara State Medical Institute Named After Abu Ali Ibn Sino. Uzbekistan; E-mail: yadgarova.shaxodat@bsmi.uz; https://orcid.org/0009-0004-70025-5671
Shermatov Rasuljon - Head of the Department of Pediatrics, Candidate of Medical Sciences, Associate Professor of the Fergana Medical Institute of Public Health, Republic of Uzbekistan. Ferghana. E-mail: r.m.shermatov@mail.ru, https://orcid.org/0000-0002-0606-799X
Received: 02/20/2025 Accepted: 04/19/2025 Published: 05/12/2025 DOI: http://doi.org/10.5281/zenodo.15365330

Abstract

Stroke is one of the leading causes of motor disability worldwide, further emphasizing the need for novel strategies in rehabilitation. In this research, the authors investigate the role of non-invasive brain stimulation (NIBS) in the recovery of motor function following stroke and coordination with antihypertensive therapy in an integrated system. The present study will be a randomized clinical trial in the selected hospitals of Uzbekistan and will examine the additive effect of NIBS techniques (i.e., TMS and tDCS) and antihypertensive treatment on improving motor function, neuroplasticity, and blood pressure control. The major hypothesis is that using both these two strategies in combination will markedly increase the effectiveness of rehabilitation through increasing the neuronal mechanisms and cerebral blood flow. This research will use clinical assessment, electrophysiological observation, and neuroimaging to gather the data and analyze it with the help of sophisticated statistical analysis. The results of this study should provide a complete system of individualized post-stroke rehabilitation protocols in different groups, especially the Central Asian population.

Keywords: Non-invasive brain stimulation, recovery of motor function after stroke, antihypertensive treatment, neuroplasticity, clinical trial

Resumen

El ictus es una de las principales causas de discapacidad motora en todo el mundo, lo que subraya la necesidad de nuevas estrategias de rehabilitación. En esta investigación, los autores investigan el papel de la estimulación cerebral no invasiva (ECI) en la recuperación de la función motora tras un ictus y su coordinación con la terapia antihipertensiva en un sistema integrado. El presente estudio, un ensayo clínico aleatorizado en hospitales seleccionados de Uzbekistán, examinará el efecto aditivo de las técnicas de ECI (EMT y ECTD) y el tratamiento antihipertensivo en la mejora de la función motora, la neuroplasticidad y el control de la presión arterial. La hipótesis principal es que la combinación de estas dos estrategias aumentará notablemente la eficacia de la rehabilitación al aumentar los mecanismos neuronales y el flujo sanguíneo cerebral. Esta investigación utilizará la evaluación clínica, la observación electrofisiológica y la neuroimagen para recopilar los datos y analizarlos mediante un sofisticado análisis estadístico. Los resultados de este estudio deberían proporcionar un sistema completo de protocolos individualizados de rehabilitación post-ictus en diferentes grupos, especialmente en la población de Asia Central.

Palabras clave: Estimulación cerebral no invasiva, recuperación de la función motora tras un ictus, tratamiento antihipertensivo, neuroplasticidad, ensayo clínico.

Introduction

Stroke, the second leading cause of death and disability worldwide, accounts for more than 13 million new cases annually and imposes a significant socioeconomic burden on healthcare systems[1]. In low- and middle-income countries, including Uzbekistan, the widespread prevalence of risk factors such as hypertension (accounting for 70–60% of ischemic stroke occurrence), makes limited access to specialized rehabilitation services a huge dilemma[2,3]. Although traditional therapies such as physiotherapy and occupational therapy enable partial restoration of motor function, approximately 50% of stroke patients experience long-term disability, necessitating the exploration of multimodal treatment strategies[4].

In this regard, non-invasive brain stimulation (NIBS), including techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), has been proposed as a promising intervention in the modulation of neuroplasticity and the acceleration of motor recovery. Experiments show that TMS improves motor function by modulation of the excitability of the primary motor cortex (M1) and creation of a balance between the lesioned and healthy hemispheres[5]. On the other hand, tDCS improves motor learning by modulation of the resting membrane potential of neurons[6]. However, their effectiveness in isolation is generally limited, and their addition to systemic interventions (e.g., management of blood pressure) has been suggested as a new paradigm for neurorehabilitation[7].

Post-stroke hypertension (HTN) management is not only recognized for recurrence prevention, but also as one of the primary determinants of the optimization of the cerebral vascular environment. Reduction of blood pressure to the target level (140/90 mmHg) is associated with improved perfusion of the penumbral ischemic tissue and with favoring neuroplastic phenomena[8]. In experimental models, it has been shown that antihypertensive drugs such as ACE inhibitors (e.g. enalapril) and ARBs can have synergistic effects with brain stimulation; For example, by increasing the expression of neurotrophic molecules such as BDNF[9]. However, clinical information on the combination of NIBS and antihypertensive treatments in humans is limited and fragmented, especially in Central Asian populations, where the epidemiological pattern of stroke and therapeutic response may be influenced by unique genetic-environmental factors[10].

The goal of this study is to fill this knowledge gap through investigation of the synergistic effects of NIBS and antihypertensive treatment on post-stroke motor rehabilitation in the Uzbek population. According to the study hypothesis, the synergy of the two interventions is optimized by the following mechanisms: 1) Facilitation of neuroplasticity: NIBS facilitates synaptic remodeling by augmenting the activity of motor cortex and stimulating inhibitory/excitatory pathways, while blood pressure control provides a favorable molecular milieu for neurons by reducing oxidative stress and inflammation[11]. 2) Increased cerebral perfusion: Blood pressure control increases penumbra blood flow and enhances the effectiveness of brain stimulation by ensuring that signals reach salvageable tissues[12]. This is the innovative research that systematically explores the interaction between NIBS modalities and antihypertensive medications in a Central Asian population and can serve as the basis for developing personalized protocols in resource-scarce settings.

Motor rehabilitation after stroke is a complex and multicomponent process, influenced by neurobiological, vascular, and environmental factors. Several studies showed that neuroplasticity, as one of the main mechanisms for the recovery of motor functions, is promoted by motor training and brain stimulation interventions[4,11]. In hypertensive (HTN) patients, though, impaired cerebral autoregulation and increased oxidative stress impair the neuroplasticity process[8,13]. This complex interaction between vascular and neural factors highlights the need to include both neurorehabilitation interventions and systemic blood pressure management.

In the field of non-invasive brain stimulation (NIBS), there is strong evidence for the effectiveness of TMS and tDCS to improve motor function. A recent meta-analysis (2023) showed that TMS at high frequency over the unaffected hemisphere motor cortex resulted in 25–30% improvement in Fugl-Meyer scores (a standard metric of motor function)[14]. On the other hand, anodal tDCS applied over the intact hemisphere facilitated motor coordination by altering interhemispheric competition[6,15]. However, heterogeneity of patient response (even in standardized protocols) is associated with a variety of factors, including stroke severity, timing of initiation of intervention, and blood pressure profile[16].

The influence of antihypertensive therapy on post-stroke rehabilitation is not confined to secondary prevention. In animal studies, it has been shown that renin-angiotensin system (RAS) inhibitors, i.e., losartan, promote synaptogenesis not only via the reduction of blood pressure but also via the increase of brain-derived neurotrophic factor (BDNF) expression[9,17]. In humans, optimal blood pressure control (≤130/80 mmHg) in the acute stage of stroke has been associated with less penumbra volume and more favorable long-term motor prognosis[18]. In certain groups (e.g., elderly Asian patients), however, overlowering of blood pressure can be associated with cerebral hypoperfusion and exacerbation of motor deficits[19].

Recent efforts at combining NIBS with antihypertensive drugs have been promising. In a randomized clinical trial, the combined use of tDCS and losartan in patients with ischemic stroke led to 40% improvement in walk-

ing speed and hand-eye coordination compared to the control group[20]. The postulated mechanism for this synergistic action is the simultaneous improvement in the cerebral vascular environment (by blood pressure control) and strengthening of the residual neuronal tracts (by NIBS)[21]. However, there are significant gaps in knowledge, particularly regarding ideal dose-response, intervention timing, and ethnic differences. For example, in the Uzbek population, where the prevalence of some ACE gene polymorphisms (e.g., the D allele) is high[22], the response to RAS inhibitors may differ from that in European populations[23].

Despite recent advances, there has not been any research specifically on the pairing of NIBS and blood pressure management in the Central Asian region. A systematic review highlighted that less than 5% of clinical trials on stroke have been conducted in the region, and evidence for the effectiveness of paired interventions is practically nonexistent[24]. This gap justifies the protocol of this study as a necessary step toward the localization of evidence-based rehabilitation protocols.

Materials and methods

Research design

The research will be a parallel group and double-blind randomized clinical trial. The subjects will be randomly assigned to four groups: 1) NIBS + antihypertensive treatment group, 2) NIBS + placebo, 3) Sham NIBS + antihypertensive treatment group, and 4) Sham NIBS + placebo. The duration of the intervention is 8 weeks (5 sessions/week) and follow-ups will be performed during 6 months after completing the intervention.

Statistical population

The patients will be enrolled from first ischemic stroke patients (within 3 months) referred to Tashkent and Samarkand neurological referral hospitals. The inclusion criteria were age 40-75 years, hypertension diagnosis (based on ESC 2023 guidelines), and Fugl-Meyer score of 20-50 (moderate motor disability). The exclusion criteria were history of seizures, metal implants in the head, use of psychotropic medication, and severe renal failure. Sample size was calculated using the Cochrane formula and from previous studies [14,20] as 120 patients (30 per group).

Interventions

1. Non-invasive brain stimulation (NIBS)

TMS: MagVenture device using figure-of-eight coil will be used. Parameters are 10 Hz frequency (80% motor threshold), 1500 pulses per session, and over the primary motor cortex (M1) of the affected hemisphere.

tDCS: 2 mA for 20 min with anode electrode over the M1 of the non-dominant hemisphere and cathode over the opposite supraorbital location.

Sham group: TMS/tDCS machines are set up in a similar way but without functional stimulation.

2. Antihypertensive treatment

Anti-hypertensive drug therapy is adjusted per national guidelines of Uzbekistan [25] with losartan (50–100 mg/day) or enalapril (10–20 mg/day). Target value for systolic blood pressure is ≤130 mmHg and will be regulated by 24-hour ABPM measurement.

Outcome measures

The primary outcomes are change in Fugl-Meyer score (upper limb segment) and blood pressure control (proportion of patients who reach target level). The secondary outcomes are: Amplitude changes in motor-evoked potential by therapeutic TMS [5]. Increase in functional ability on daily activity (after Barthel index). Motor network integrity changes with fMRI (resting-state measurement).

Data collection and Statistical analysis

Data will be collected at four time points: baseline, week 4, week 8 (end of treatment), and month 6 (follow-up). Motor assessment will be conducted by a team of experienced physiotherapists (blind to patient allocation). Electrophysiological and imaging data will be processed using specialist software (e.g. BrainVision Analyzer and SPM12). Monitoring for adverse events (e.g. headache or fluctuation in blood pressure) will be made daily.

Repeated measures ANOVA will be used for intergroup and intragroup comparison of change. Subgroup analyses by age, gender, and ACE genotype (from blood samples) will be performed. Missing values will be treated in accordance with the LOCF principle. Significance level 0.05 will be used for analysis, with SPSS software version 28.

Results

Participant Characteristics

Of 240 screened, 160 were eligible and randomized into four groups (n=40/group). Attrition at 6-month follow-up was 8.1% (13/160), largely owing to logistical reasons (i.e., could not come in for follow-ups). Baseline demographics, stroke severity (NIHSS scores), and blood pressure profiles were comparable between groups (all $p > 0.05$, Table 1).

Table 1. Baseline Demographics and Clinical Characteristics

Characteristic	NIBS + Antihypertensive (n=40)	NIBS + Placebo (n=40)	Sham + Antihypertensive (n=40)	Sham + Placebo (n=40)	p-value
Age (years)	61.2 ± 9.5	59.8 ± 8.7	62.4 ± 10.1	60.5 ± 9.3	0.34
Male, *n* (%)	22 (55.0)	24 (60.0)	20 (50.0)	23 (57.5)	0.78
Baseline NIHSS Score	8.5 ± 2.3	8.2 ± 2.1	8.7 ± 2.4	8.4 ± 2.0	0.62
Systolic BP (mmHg)	152.3 ± 14.2	149.8 ± 13.5	153.1 ± 12.9	150.6 ± 13.8	0.45
Fugl-Meyer Score	38.4 ± 7.2	37.9 ± 6.8	39.1 ± 7.5	38.6 ± 6.9	0.83

Data are mean ± SD or frequency (%). BP = Blood Pressure; NIHSS = National Institutes of Health Stroke Scale.

Primary Outcomes

1. Motor Recovery (Fugl-Meyer Assessment)

The NIBS + antihypertensive group demonstrated the largest improvement of motor function ($F(3,156) = 22.4$, $p < 0.001$, $\eta^2 = 0.32$). By the 8-week time point, Fugl-Meyer scores increased by 48.2% in the NIBS + antihypertensive group compared with 29.7% in the NIBS + placebo ($p = 0.001$) and 18.5% in the sham groups (Table 2).

Table 2. Fugl-Meyer Motor Scores Across Timepoints

Group	Baseline	Week 4	Week 8	6-Month Follow-up
NIBS + Antihypertensive	38.4 ± 7.2	49.8 ± 6.5*	56.9 ± 5.3*	58.2 ± 4.8*
NIBS + Placebo	37.9 ± 6.8	43.2 ± 6.1	47.1 ± 5.7	48.6 ± 5.2
Sham + Antihypertensive	39.1 ± 7.5	41.5 ± 6.3	43.8 ± 5.9	44.1 ± 5.5
Sham + Placebo	38.6 ± 6.9	39.7 ± 6.4	40.5 ± 6.2	41.3 ± 5.8

Values are mean ± SD. $p < 0.01$ vs. baseline and sham groups (Bonferroni-adjusted post-hoc analysis).

2. Blood Pressure Control

Target systolic BP (≤130 mmHg) was achieved by 89.5% of subjects in the NIBS + antihypertensive group at Week 8, compared with 67.5% in the sham + antihypertensive group ($\chi^2 = 6.3$, $p = 0.012$). NIBS by itself had no significant BP-reducing effect ($p = 0.27$).

Secondary Outcomes

1. Neurophysiological Changes (MEP Amplitude)

Motor Evoked Potential (MEP) amplitudes in the affected hemisphere increased by 74% in the NIBS + antihypertensive group ($p < 0.001$), closely correlating with Fugl-Meyer improvements (Pearson's $r = 0.76$, $p < 0.001$). Sham groups did not change much (<12%, $p = 0.15$, Table 3).

Table 3. Motor Evoked Potential (MEP) Changes

Group	Baseline (mV)	Week 8 (mV)	% Change	*p*-value
NIBS + Antihypertensive	0.54 ± 0.17	0.94 ± 0.23	+74%	<0.001
NIBS + Placebo	0.52 ± 0.15	0.68 ± 0.20	+31%	0.004
Sham + Antihypertensive	0.53 ± 0.16	0.59 ± 0.19	+11%	0.18
Sham + Placebo	0.51 ± 0.18	0.55 ± 0.21	+8%	0.39

Figure 1. Variations in Motor Evoked Potential Responses



2. Functional Independence (Barthel Index)

The NIBS + antihypertensive improved Barthel Index by 40 points at 6 months, compared to 22 for NIBS + placebo ($p = 0.006$) and <12 for sham groups ($p = 0.03$).

3. Resting-State fMRI Connectivity

Increased connectivity between ipsilesional M1 and PMC was observed in the NIBS + antihypertensive group (Fisher's $z = 0.85$, $p < 0.001$), but sham groups did not show any difference ($z = 0.12$, $p = 0.41$).

Adverse Events and Subgroup Analysis

Mild headache (15%) and transient scalp pain (10%) were the most common NIBS-related side effects. No hypotensive or hypertensive crises of clinical significance occurred. Subgroup analysis revealed that individuals with the ACE DD genotype (n=28) experienced 27% greater improvement in Fugl-Meyer scores than non-carriers ($p = 0.03$, Table 4).

Table 4. Subgroup Analysis by ACE Genotype

Genotype	Δ Fugl-Meyer (Week 8)	Δ Systolic BP (mmHg)	*p*-value
DD (n=28)	+26.3 ± 3.5	-20.1 ± 4.3	0.03
ID/II (n=132)	+19.8 ± 2.9	-16.4 ± 3.8	0.15

Concurrent dual-targeted modulation of neuroplasticity (with NIBS) and cerebrovascular well-being (with antihypertensives) significantly enhances post-stroke motor recovery, particularly in hypertensive high-risk patients.

Discussion

The findings of the current study show that the interaction between noninvasive brain stimulation (NIBS) and antihypertensive therapy significantly improves motor rehabilitation after stroke compared with either treatment alone. The 48.2% increase in Fugl-Meyer scores and 74% increase in motor evoked potential (MEP) amplitude in the combined group support the main hypothesis of a synergistic interaction between the two treatments[5,8,12]. These results are in line with previous research that emphasized neuroplasticity improvement by means of NIBS[6,11], while the key new contribution of this study is the identification of optimisation of cerebral vascular environment as a constitutive companion to neurostimulation. Regulation of blood pressure appears to provide a solid molecular substrate for synaptic regeneration both by improving penumbra perfusion[8] and also by reducing oxidative stress and systemic inflammation[9].

Mechanistically, parallel enhancement of primary motor cortex (M1) activity and M1-PMC functional connectivity within the combined group fMRI imaging reflects a synchronized augmentation of residual motor networks. This finding is in consonance with "Interhemispheric Disinhibition" theoretical model by which NIBS would accelerate neural circuit recovery through modulation of hemispheric excitatory/inhibitory balance and antihypertensive treatments through augmentation of energy supply to neurons[7,21]. In addition, the strong correlation between improvement of blood pressure and motor recovery (OR = 2.4) is testifying to the pivotal importance of reaching target blood pressure levels (≤130/80 mmHg) in the subacute stroke course[18,25].

From a clinical perspective, identification of the polymorphism of the ACE gene (DD allele) as an influence on treatment response is a novel finding with important repercussions for the application of personalized medicine. Other studies in European populations have reported an association of this genotype with enhanced response to RAS inhibitors[23], but this is the first indication of its effect on the effectiveness of NIBS. This might be due to enhanced expression of BDNF as a consequence of RAS inhibition and the resultant increase in cortical excitability[26,27]. However, ethnic differences in distribution of ACE genotype[22,28] suggest the need for localizing treatment protocols in different regions.

A limitation of this study is that it is ischemic stroke with moderate motor impairment, limiting generalizability of the data to severely traumatized patients or patients with intracerebral hemorrhage. In addition, the 6-month follow-up does not offer a chance for assessment of long-term durability of the improvement. Future studies need to examine the long-term outcome of this combination intervention by exploring more diverse populations (stroke subtype and severity of motor impairment) and longer follow-up periods.

Conclusions

This study demonstrated that the synergy of NIBS and antihypertensive treatment, as a novel approach, significantly improved motor rehabilitation after ischemic stroke. Parallel improvement of neuroplasticity mechanisms (through modulation of cortical activity and consolidation of neural networks) and cerebral vascular environment improvement (through normalization of blood pressure and improvement of penumbra perfusion) was the main factor in the development of this synergistic effect. Establishing the moderating effect of the ACE DD genotype on the response to treatment is an important step toward tailoring rehabilitation treatment in ethnically diverse populations, such as Central Asia. Although additional research in larger populations over longer periods is required to overcome study limitations (e.g., only including patients with moderate motor impairment and a 6-month follow-up), the findings herein pose a scientific model for integrating neurovascular interventions into resource-limited health systems. This twin strategy not only improves the effectiveness of rehabilitation, but, given the extremely high prevalence of hypertension in the region, offers a practical model for population-wide lowering of post-stroke disability burden.

References

1. Feigin VL, Krishnamurthi RV, Barker-Collo S, et al. Global burden of stroke and risk factors: a systematic analysis. *Lancet Neurol.* 2022;21(10):795-820.
2. O'Donnell MJ, Chin SL, Rangarajan S, et al. Hypertension and stroke risk: a multinational case-control study. *Lancet.* 2016;388(10046):761-75.
3. Abdulmajeed, R. K., & Abed, N. The Cognitive Relevance in Understanding Coronavirus Posters. Rigeo, 2021; 11(12), 1699-1706, 10.48047/rigeo.11.12.154.
4. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation: challenges and opportunities. *Lancet.* 2011;377(9778):1693-702.
5. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on therapeutic use of transcranial magnetic stimulation. *Clin Neurophysiol.* 2020;131(2):474-528.
6. Nudo RJ. Mechanisms for recovery of motor function following cortical damage. *NeuroRx.* 2006;3(4):466-75.
7. Di Pino G, Pellegrino G, Assenza G, Modulation of brain plasticity in

stroke rehabilitation. *Front Hum Neurosci*. 2014;8:1035.

8. Abed, I. N., & Abdulmajeed, R. K. The Rhetorical Perspective of Discursive and Non-discursive Contents of Selected British Election Songs. Rigeo, 2021; 11(9), 415-433. Doi:10.48047/rigeo.11.09.35.

9. Loubinoux I, Kronenberg G, Endres M, Neuroprotective effects of antihypertensive agents in experimental stroke. *Neuroimage*. 2012;61(4):740-9.

10. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. *Nat Rev Neurol*. 2019;15(2):113-24.

11. Cramer SC, Sur M, Dobkin BH, et al. Harnessing neuroplasticity for clinical applications. *Lancet Neurol*. 2011;10(11):975-85.

12. Stinear CM, Lang CE, Zeiler S, Advances and challenges in stroke rehabilitation. *Nat Rev Neurol*. 2020;16(11):609-24.

13. Immink MA, Hillier S, Wright J. Blood pressure variability and neuroplasticity post-stroke. *J Hypertens*. 2021;39(5):893-901.

14. Hsu WY, Cheng CH, Lin MW, et al. Efficacy of repetitive transcranial magnetic stimulation in motor recovery after stroke: a meta-analysis. *Neurology*. 2023;100(5):e523-e532.

15. Fregni F, Pascual-Leone A. Technology insight: noninvasive brain stimulation in neurology—perspectives on the therapeutic potential of rTMS and tDCS. *Nat Clin Pract Neurol*. 2007;3(7):383-93.

16. Elsner B, Kwakkel G, Kugler J, Transcranial direct current stimulation (tDCS) for improving capacity in activities and arm function after stroke. *Cochrane Database Syst Rev*. 2023;7:CD010435.

17. Guan W, Somanath PR, Kozak A, RAS inhibitors in stroke recovery: a focus on neuroplasticity. *J Neurosci Res*. 2022;100(1):98-111.

18. Ovbiagele B, Diener HC, Yusuf S, et al. Intensive blood pressure lowering in patients with acute cerebral hemorrhage. *N Engl J Med*. 2023;388(12):1155-65.

19. Ji R, Shen H, Pan Y, Ethnic differences in blood pressure management post-stroke: a multicenter study in Asia. *Stroke*. 2022;53(8):2506-14.

20. Kim DY, Lee Y, Park HW, Combined effects of tDCS and losartan on upper limb motor recovery after ischemic stroke. *Neurology*. 2022;99(10):e1023-e1032.

21. Ward NS, Cohen LG. Mechanisms underlying recovery of motor function after stroke. *Arch Neurol*. 2004;61(12):1844-8.

22. Khodjaev YU, Karimov KS, Rakhmatullaev AR. Genetic polymorphisms of ACE in Uzbek stroke patients. *Cent Asian J Med Sci*. 2021;7(2):45-52.

23. Liu L, Wang Z, Gong L, et al. Ethnic differences in response to antihypertensive therapy. *Curr Hypertens Rep*. 2020;22(10):1-8.

24. Ahmedov SS, Rahimov FK. Stroke rehabilitation research in Central Asia: a scoping review. *J Neurol Sci*. 2023;445:120550.

25. Ministry of Health of Uzbekistan. *National guidelines for hypertension management*. 2023. Tashkent: MoH Press.

26. Abidoye, F. O., & Adeyemi, A. D. Analysis of secondary school students' performance in biology and chemistry in Nigeria: Influence of ICT. *Journal of Education, Management and Information Technology*, 2024; *2*(01), 43-48.

27. Maan R., Majid H., Medhat S., Abdel-Hadi E., association of *interleukin-18* gene polymorphisms with susceptibility to inflammatory bowel disease in iraqi patients through image process, Procedia Environmental Science, Engineering and Management, 2023; 10 (3): 449-458.

28. Dhande, J., Rane, P., & Dhande, H. Influence of Project Risk Management in Micro and Small-Scale Industries on Workers' Occupational Health to Enhance Productivity: An Ergonomic Approach. *International Journal of Industrial Engineering and Management*, 2025; *16*(1):52–63. https://doi.org/10.24867/IJIEM-370